Therapeutic Degraders as New Class of Prostate Cancer Treatments

Session 2: Therapeutic Degraders as New Class of Prostate Cancer Treatments
Thursday, October 28, 2021 | 8:45 AM – 9:25 AM PST

Moderator: Howard Soule, PhD, Prostate Cancer Foundation

Targeting Enhancer Addiction in Prostate Cancer by Impeding Chromatin Accessibility
Arul M. Chinnaiyan, MD, PhD, University of Michigan, Michigan Center for Translational Pathology

Clinical Development of ARV-110, a Novel AR Degrader, in Prostate Cancer
Debbie Chirnomas, MD, MPH, Arvinas, Inc.

82 cents of every dollar donated goes to our prostate cancer research mission

Join the fight against prostate cancer today. Donate